Cognitive impairment affects 40-70% of patients with MS, across all phenotypes. Patients may experience multiple cognitive deficits, which can impact processing speed, attention, executive function, working memory, and visuospatial memory. Dr Elisa Colato (Amsterdam UMC, the Netherlands) noted that recent studies have applied ML to identify cross-sectional CPs in MS, but did not capture how cognitive damage evolves. Dr Colato and colleagues aimed to identify data-driven CPs and their progression patterns in MS [1]. They used Subtype and Stage Inference (SuStaIn), an unsupervised ML approach combining clustering with disease progression modelling. By assessing associations with future disability, the clinical relevance of CPs was determined.
Using retrospective, longitudinal data from 3,407 MS patients, the model was validated internally in a training cohort and externally in an independent cohort. 3 cognitive phenotypes were identified, with a distinct progression pattern:
- Verbal memory-led;
- Verbal fluency and visuospatial/processing speed-led;
- Executive function and processing speed-led.
The longitudinal stability of these phenotypes was assessed in both cohorts, with follow-ups of 2 years (training) and 1 year (external). In the training cohort (n=779), the initial subtype was maintained by 94% at 1 year, 57% at 3 years, and 37% at 5 years. In the external cohort (n=493), stability rates were 93%, 84%, and 51%, respectively. In the executive function and processing speed-led group, which also showed the highest rate of cognitive impairment, there was a significant association with future disability (P<0.05).
Dr Colato concluded that these findings may improve disease monitoring and inform the development of tailored interventions. Further research is needed to identify the underlying patterns of cognitive damage.
- Colato E, et al. Identifying cognitive phenotypes and their progression patterns in multiple sclerosis using a machine learning model. O091, ECTRIMS 2025 Congress, 24-26 September 2025, Barcelona, Spain.
Medical writing support was provided by Michiel Tent.
Copyright ©2025 Medicom Medical Publishers
Posted on
Previous Article
« Ocrelizumab established as a new option for children with MS Next Article
Menopause may alter the course of MS »
« Ocrelizumab established as a new option for children with MS Next Article
Menopause may alter the course of MS »
Table of Contents: ECTRIMS 2025
Featured articles
Novel anti-CD20 antibody shows efficacy in AQP4-IgG-positive NMOSD
Ocrelizumab delays disability progression in older patients with PPMS
Applying the new McDonald criteria increases the rate of MS diagnosis
Online First
Mesenchymal stem cells show no neuroregenerative benefit in PMS
Equal impact of high- and moderate-efficacy therapies on PIRMA
Novel anti-CD20 antibody shows efficacy in AQP4-IgG-positive NMOSD
Halving the yearly rituximab dose maintains efficacy in RRMS
High-dose ocrelizumab has no additional benefit in PPMS
Machine learning enables personalised prediction of cognitive decline in MS
Ocrelizumab established as a new option for children with MS
Small remyelinating effect of metformin plus clemastine
Ocrelizumab delays disability progression in older patients with PPMS
Maintenance MOGAD therapy can be safely discontinued
Anti-CD20 therapies outperform platform DMTs in prepubertal MS
Live attenuated MMR and varicella vaccines do not increase relapse risk
Caution is needed when discontinuing DMT in individuals under 60
Applying the new McDonald criteria increases the rate of MS diagnosis
Related Articles
September 30, 2025
Novel anti-CD20 antibody shows efficacy in AQP4-IgG-positive NMOSD
December 20, 2022
Humoral and cellular immune responses after SARS-CoV-2 vaccination
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com
